Form 4: Serina Therapeutics CSO Sells Shares

Sentiment:

Insider Transaction Report 14 August 2025 4:27 PM

📋All filings for Serina Therapeutics, INC

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold 5,500 shares for a weighted average price of $5.25 per share.

Summary

Chief Scientific Officer Randall Moreadith exercised 5,500 stock options at an exercise price of $0.06 per share.
Simultaneously, 5,500 shares of common stock were sold at a weighted average price of $5.25 per share.
The sale prices for the shares ranged from $5.13 to $5.36.
The transaction was conducted pursuant to a Rule 10b5-1 trading plan.
Following these transactions, Randall Moreadith holds 0 shares of common stock directly and 473,490 stock options directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise and immediate sale of stock options under a pre-arranged trading plan, which is generally neutral in sentiment.

Positives

Chief Scientific Officer Randall Moreadith realized a profit by exercising options at $0.06 and selling shares at an average of $5.25.
The stock options exercised were fully vested, indicating no future vesting requirements for these specific options.

Negatives

Chief Scientific Officer Randall Moreadith sold all 5,500 shares acquired through the option exercise, resulting in zero direct beneficial ownership of common stock after the transaction.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders may view the insider sale as a signal, though the transaction being under a Rule 10b5-1 plan mitigates potential negative perceptions as it was pre-scheduled.

Key Dates

Date	Description
05/06/2031	Expiration date of the exercised stock options.
08/12/2025	Date of the stock option exercise and subsequent sale of common stock.
08/14/2025	Date the Form 4 was signed by Randall Moreadith.

Recommendation

hold

The filing details a pre-scheduled insider sale by a Chief Scientific Officer, which is a common occurrence for compensation and personal financial planning. It does not provide new information regarding the company's operational performance or strategic direction that would warrant a change in investment thesis. The transaction was executed under a Rule 10b5-1 plan, suggesting it was not based on new material non-public information.

Keywords

Serina Therapeutics, SER, Form 4, insider trading, stock options, share sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.